The Impact of Human Vaccines on Bacterial Antimicrobial Resistance. A Review

Overview

Journal Environ Chem Lett

Specialty Chemistry

Date 2021 Oct 4

PMID 34602924

Citations 20

Authors

Kathrin U Jansen

William C Gruber

Raphael Simon

James Wassil

Annaliesa S Anderson

Affiliations

Soon will be listed here.

Abstract

At present, the dramatic rise in antimicrobial resistance (AMR) among important human bacterial pathogens is reaching a state of global crisis threatening a return to the pre-antibiotic era. AMR, already a significant burden on public health and economies, is anticipated to grow even more severe in the coming decades. Several licensed vaccines, targeting both bacterial ( type b, , serovar Typhi) and viral (influenza virus, rotavirus) human pathogens, have already proven their anti-AMR benefits by reducing unwarranted antibiotic consumption and antibiotic-resistant bacterial strains and by promoting herd immunity. A number of new investigational vaccines, with a potential to reduce the spread of multidrug-resistant bacterial pathogens, are also in various stages of clinical development. Nevertheless, vaccines as a tool to combat AMR remain underappreciated and unfortunately underutilized. Global mobilization of public health and industry resources is key to maximizing the use of licensed vaccines, and the development of new prophylactic vaccines could have a profound impact on reducing AMR.

Citing Articles

Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria.

Mourabiti F, Jouga F, Sakoui S, El Hosayny O, Zouheir Y, Soukri A Arch Microbiol. 2025; 207(3):58.

PMID: 39948320 DOI: 10.1007/s00203-025-04252-z.

Synthesis and Structure-Activity Relationship (SAR) Studies on New 4-Aminoquinoline-Hydrazones and Isatin Hybrids as Promising Antibacterial Agents.

Ubaid A, Shakir M, Ali A, Khan S, Alrehaili J, Anwer R Molecules. 2024; 29(23).

PMID: 39683935 PMC: 11643852. DOI: 10.3390/molecules29235777.

Trivalent immunization with metal-binding proteins confers protection against enterococci in a mouse infection model.

Lam L, Sedra A, Kajfasz J, Berges A, Saengpet I, Adams G FEMS Microbes. 2024; 5:xtae031.

PMID: 39524556 PMC: 11549557. DOI: 10.1093/femsmc/xtae031.

Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.

Miller J, Cross A, Tennant S, Baliban S Vaccines (Basel). 2024; 12(10).

PMID: 39460343 PMC: 11512408. DOI: 10.3390/vaccines12101177.

Influence of immunological awareness on enhancing the overall complying with health instructions and necessary vaccines during epidemics and pandemics.

Almansour Z Hum Vaccin Immunother. 2024; 20(1):2406066.

PMID: 39314074 PMC: 11423657. DOI: 10.1080/21645515.2024.2406066.

References

Elbahesh H, Saletti G, Gerlach T, Rimmelzwaan G . Broadly protective influenza vaccines: design and production platforms. Curr Opin Virol. 2018; 34:1-9. DOI: 10.1016/j.coviro.2018.11.005. View

Hsu D, OConnell R . Progress in HIV vaccine development. Hum Vaccin Immunother. 2017; 13(5):1018-1030. PMC: 5443372. DOI: 10.1080/21645515.2016.1276138. View

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

Levine M, Simon R . The Gathering Storm: Is Untreatable Typhoid Fever on the Way?. mBio. 2018; 9(2). PMC: 5874914. DOI: 10.1128/mBio.00482-18. View

Kohanski M, Dwyer D, Collins J . How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010; 8(6):423-35. PMC: 2896384. DOI: 10.1038/nrmicro2333. View

Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A . Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011; 29(40):7009-19. DOI: 10.1016/j.vaccine.2011.07.033. View

Gellatly S, Hancock R . Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013; 67(3):159-73. DOI: 10.1111/2049-632X.12033. View

Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T . Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun. 2005; 73(12):8027-32. PMC: 1307051. DOI: 10.1128/IAI.73.12.8027-8032.2005. View

Alderson M . Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016; 34(26):2959-2961. PMC: 4906266. DOI: 10.1016/j.vaccine.2016.03.107. View

10.

van den Dobbelsteen G, Fae K, Serroyen J, van den Nieuwenhof I, Braun M, Haeuptle M . Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine. 2016; 34(35):4152-4160. DOI: 10.1016/j.vaccine.2016.06.067. View

11.

Gagneux-Brunon A, Lucht F, Launay O, Berthelot P, Botelho-Nevers E . Vaccines for healthcare-associated infections: present, future, and expectations. Expert Rev Vaccines. 2018; 17(5):421-433. DOI: 10.1080/14760584.2018.1470507. View

12.

Ncho H, Masunda K, Mukeredzi I, Manangazira P, Govore E, Duri C . Notes from the Field: Typhoid Fever Outbreak - Harare, Zimbabwe, October 2017-February 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(2):44-45. DOI: 10.15585/mmwr.mm6802a5. View

13.

Parry C, Ribeiro I, Walia K, Rupali P, Baker S, Basnyat B . Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities. BMJ. 2019; 364:k5322. PMC: 6340381. DOI: 10.1136/bmj.k5322. View

14.

Breiman R, Butler J, Tenover F, Elliott J, Facklam R . Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994; 271(23):1831-5. View

15.

Olaru I, Mtapuri-Zinyowera S, Feasey N, Ferrand R, Kranzer K . Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe. Lancet Infect Dis. 2019; 19(9):930. DOI: 10.1016/S1473-3099(19)30425-6. View

16.

Forthal D . Functions of Antibodies. Microbiol Spectr. 2014; 2(4):1-17. PMC: 4159104. View

17.

Magill S, Edwards J, Bamberg W, Beldavs Z, Dumyati G, Kainer M . Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370(13):1198-208. PMC: 4648343. DOI: 10.1056/NEJMoa1306801. View

18.

Hirschtick R, Glassroth J, Jordan M, Wilcosky T, Wallace J, Kvale P . Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 333(13):845-51. DOI: 10.1056/NEJM199509283331305. View

19.

Were T, Davenport G, Hittner J, Ouma C, Vulule J, Ongecha J . Bacteremia in Kenyan children presenting with malaria. J Clin Microbiol. 2010; 49(2):671-6. PMC: 3043473. DOI: 10.1128/JCM.01864-10. View

20.

Betsch C, Brewer N, Brocard P, Davies P, Gaissmaier W, Haase N . Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine. 2012; 30(25):3727-33. DOI: 10.1016/j.vaccine.2012.02.025. View